Clinuvel Pharmaceuticals (CUV) Stock Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

CUV Stock Information

Symbol

CUV

Address

535 Bourke StreetMelbourne, VIC 3000Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.clinuvel.com

Country

🇦🇺 Australia

Phone Number

61 3 9660 4900

Clinuvel Pharmaceuticals (CUV) Price Chart

Clinuvel Pharmaceuticals Overview: Key Details and Summary

Stock data	2023	Change
Price	$9.13	N/A
Market Cap	$451.10M	N/A
Shares Outstanding	49.41M	0.00%
Employees	0	N/A
Shareholder Equity	164.63M	31.12%

Valuation	2023	Change
P/E Ratio	15.45	N/A
P/S Ratio	8.50	N/A
P/B Ratio	2.74	N/A

Growth	2023	Change
Return on Equity	0.1259	N/A

Earnings	2023	Change
Revenue	$53.04M	N/A
Earnings	$20.73M	N/A
EPS	0.591	N/A
Earnings Yield	0.0647	N/A
Gross Margin	0.8878	N/A
Operating Margin	0.5631	N/A
Net income margin	0.3908	N/A

Financial Strength	2023	Change
Total Assets	$131.20M	N/A
Total Debt	$677.18K	N/A
Cash on Hand	$106.20M	N/A
Debt to Equity	0.1196	20.61%
Cash to Debt	$156.83	62.18%
Current Ratio	$7.44	-27.35%